Tudor Investment Corp ET AL Boosts Holdings in Avanos Medical, Inc. $AVNS

Tudor Investment Corp ET AL grew its position in shares of Avanos Medical, Inc. (NYSE:AVNS) by 509.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 71,893 shares of the company’s stock after buying an additional 60,099 shares during the quarter. Tudor Investment Corp ET AL’s holdings in Avanos Medical were worth $831,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the company. Versant Capital Management Inc lifted its stake in shares of Avanos Medical by 49.7% in the 3rd quarter. Versant Capital Management Inc now owns 2,692 shares of the company’s stock worth $31,000 after acquiring an additional 894 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Avanos Medical by 4.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company’s stock worth $386,000 after acquiring an additional 1,121 shares during the period. Azzad Asset Management Inc. ADV increased its stake in shares of Avanos Medical by 3.0% during the third quarter. Azzad Asset Management Inc. ADV now owns 43,230 shares of the company’s stock worth $500,000 after acquiring an additional 1,240 shares during the period. Federated Hermes Inc. raised its holdings in Avanos Medical by 6.9% during the third quarter. Federated Hermes Inc. now owns 25,083 shares of the company’s stock worth $290,000 after purchasing an additional 1,612 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its holdings in Avanos Medical by 969.3% during the second quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock worth $31,000 after purchasing an additional 2,307 shares in the last quarter. Institutional investors and hedge funds own 95.17% of the company’s stock.

Avanos Medical Stock Up 1.6%

AVNS opened at $13.73 on Tuesday. The business’s fifty day moving average is $13.85 and its two-hundred day moving average is $12.38. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.26 and a current ratio of 2.15. The company has a market cap of $638.58 million, a price-to-earnings ratio of -8.69 and a beta of 1.07. Avanos Medical, Inc. has a one year low of $9.30 and a one year high of $15.68.

Avanos Medical (NYSE:AVNS) last posted its earnings results on Tuesday, February 24th. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.05. The company had revenue of $180.90 million for the quarter, compared to analyst estimates of $174.70 million. Avanos Medical had a positive return on equity of 5.47% and a negative net margin of 10.40%.Avanos Medical’s revenue was up .7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.43 earnings per share. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. Analysts anticipate that Avanos Medical, Inc. will post 1.32 EPS for the current fiscal year.

Analysts Set New Price Targets

AVNS has been the subject of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Avanos Medical in a research report on Monday, December 22nd. Wall Street Zen raised Avanos Medical from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Zacks Research raised Avanos Medical from a “strong sell” rating to a “hold” rating in a report on Monday, January 26th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Avanos Medical has an average rating of “Reduce”.

Avanos Medical Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.